Prescription patterns of first- and second-generation antipsychotic drugs in the French population.
antipsychotic drugs
national insurance based-study
pharmaco-epidemiology
service use
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
02
04
2019
revised:
26
12
2019
accepted:
28
02
2020
pubmed:
8
3
2020
medline:
9
6
2021
entrez:
8
3
2020
Statut:
ppublish
Résumé
This study assessed in depth the use of first- and second-generation antipsychotic (FGAP/SGAP) drugs in France. A 1/97th random sample of beneficiaries affiliated to the French Health Insurance system-Echantillon Généraliste des Bénéficiaires (EGB)-was used: (i) 621 662 persons in 2015 among which 11 319 had an antipsychotic (AP) prescription; (ii) a sample of first AP prescriptions concerning 5 935 patients in 2013 and 2014 (no AP in the last 6 months of 2012) for whom diagnosis was available in 40% of cases. In 2015, AP prevalence was 21.9/1 000. SGAP/FGAP ratio was 1.02. Long-lasting prescriptions were rare: 1.79/1 000 for FGAP and 1.38/1 000 for SGAP. FGAP first prescriptions were higher than SGAP for each age class, except for <18 aged patients; 2.85% had both generations; 50.7% of the patients had another psychotropic. GPs prescribed more FGAPs than SGAPs, psychiatrists prescribed more SGAPs and hospital-based practitioners prescribed both generations equally, and these patterns changed across age ranges: For the elderly, GPs are the more frequent prescribers. SGAP/FGAP ratio is different by diagnostic categories. In France, FGAPs are largely prescribed by GPs mainly for the elderly, but young and adult patients are concerned as well. Inappropriate antipsychotic consumption through off-label use, which adds to the co-prescription, especially in vulnerable population groups, mainly concerns FGAP prescriptions by GPs who do not have psychiatric training and limited contact with psychiatrists. Attention should then be brought to the regulatory advisory agencies in order to better inform and train the prescribers.
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-611Subventions
Organisme : Fondation Pierre Deniker pour la Recherche et la Prévention en Santé Mentale
ID : none
Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
Pincus H.A., Tanielian T.L., Marcus S.C. et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA (1998) 279 526-531.
Verdoux H., Tournier M., Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr. Scand. (2010) 121 4-10.
Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ (2000) 321 1371-1376.
Zimmerman M., Ruggero C.J., Chelminski I., Young D. Is bipolar disorder overdiagnosed? J. Clin. Psychiatry (2008) 69 935-940.
Olfson M., Blanco C., Liu L., Moreno C., Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry (2006) 63 679-685.
Dewa C.S., Remington G., Herrmann N., Fearnley J., Goering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin. Ther. (2002) 24 1466-1476.
Lindesay J., Matthews R., Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int. J. Geriatr. Psychiatry (2003) 18 511-519.
Halfdanarson O., Zoega H., Aagaard L. et al. International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur. Neuropsychopharmacol. (2017) 27 1064-1076.
Désaméricq G., Schürhoff F., Macquin-Mavier I., Bachoud-Lévi A.-C., Maison P. Use of antipsychotics: a study from the french national insurance healthcare system database. Pharmacol. Pharm. (2015) 6 411-419.
Verdoux H., Pambrun E., Cortaredona S., Tournier M., Verger P. Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. Eur. Child Adolesc. Psychiatry (2015) 24 1181-1191.
Bezin J., Duong M., Lassalle R. et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol. Drug Saf. (2017) 26 954-962.
Gallini A., Donohue J.M., Huskamp H.A. Diffusion of Antipsychotics in the U.S. and French Markets, 1998-2008. Psychiatr. Serv. (2013) 64 680-687.
Verdoux H., Pambrun E., Tournier M., Bezin J., Pariente A. Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophr. Res. (2016) 178 58-63.
Verdoux H., Pambrun E., Tournier M., Bezin J., Pariente A. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr. Scand. (2017) 135 429-438.
H.A.S., 2007. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/guide_ald23_schizophr_juin_07.pdf
H.A.S., 2012. Available from: https://www.has-sante.fr/portail/jcms/c_937781/fr/prise-au-long-cours-d-hypnotiques-anxiolytiques
Prescrire. Neuroleptiques: trop banalisés. Prescrire (2016) 36 855.
H.A.S., 2011. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/anti_psychotiques_rapport.pdf
SC S. The complete drug reference, 35th Revised edn. London, 2006.
HAS. REFERENTIEL DE CERTIFICATION De l'activité d'information par démarchage ou prospection visant à la promotion des medicaments, 2017. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-04/dir3/referentiel_de_certification_ip_mars_2017.pdf
C.O.M. Atlas de la démographie médicale, 2015. Available from: https://www.conseil-national.medecin.fr/sites/default/files/atlas_national_de_la_demographie_medicale_2015.pdf
Verdoux H., Pambrun E., Tournier M., Cortaredona S., Verger P. Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample. Acta Psychiatr. Scand. (2019) 139 536-547.
HCSP. Évaluation du plan psychiatrie et santé mentale 2011-2015. Paris, France, 2016.
Nijk R.M., Zuidema S.U., Koopmans R.T. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int. Psychogeriatr. (2009) 21 485-493.
Woolcott J.C., Richardson K.J., Wiens M.O. et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch. Intern. Med. (2009) 169 1952-1960.
Kovess-Masfety V., Alonso J., Brugha T.S. et al. Differences in lifetime use of services for mental health problems in six European countries. Psychiatr. Serv. (2007) 58 213-220.
Buzyn A.Il faut préserver les moyens de la psychiatrie. Le monde, 2018(26/01/2018).